Sanjiv Bhasin, executive vice president, markets & corporate affairs at IIFL says domestic markets have been able to delink themselves from weak global cues. (Watch)
Stock Talk
Dr Reddy's Lab: Despite the run up, it may still offer a bit of upside; quarterly numbers have shown growth.
Cipla: The stock has seen a downside after the results. Cipla's model is such that it keeps innovating and with certain drug approvals having come through in Europe, sales will start to kick in.
Tata Elxsi: The stock has outperformed, so investors should book profits now. All the way from Rs 1,100, we have been recommending profit booking.
NIIT Tech: Bullish on the stock. Any decline is an opportunity to get into the stock.
Tata Motors: At Rs 350, it is a buy. All the negatives have been priced in including China slowdown and JLR. The commercial vehicle (CV) segment is picking up and CV will be an outperformer in the domestic market.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
